

Special Issue

Clinical Proteomics in Proliferative Disorders

Message from the Guest Editors

Neoplastic and non-neoplastic disorders of human pathology encompass a wide spectrum of disease states with various prognostics. Our ultimate goal is to discover and implement diagnostic and therapeutic tools to improve outcomes and the life quality of patients. In recent decades, we have witnessed the advent of transcriptomics and genomics which today are the cornerstones of clinical decision making in modern molecularly driven therapeutics. Proteomics will bridge the gap between genetics and the resulting phenotypes, which will also improve our understanding of human diseases like never before. In this Special Issue, we seek contributions which improve our understanding of tumor biology or non-neoplastic proliferative disorders with a direct implication for patient care. Results of measurements performed on human tissue or clinical data are encouraged. Original reports, review articles, meta-analyses, and clinical trial reports which contain protein-level investigation with direct implication in patient care are also welcome.

Guest Editors

Dr. Attila Marcell Szász

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary

Dr. György Marko-Varga

Department of Biomedical, Engineering, Lund University, 22100 Lund, Sweden

Deadline for manuscript submissions

closed (30 March 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/88280

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)